Sight for Life
Personalized Flow. IOP Control.
Designed to be the first-of-its-kind treatment that allows maximum IOP reduction for patients with moderate to severe glaucoma.
Aims to Deliver IOP Control
Personalized flow for evolving patient needs
Personalized flow for evolving patient needs
Safety Without Sacrificing Efficacy
Intends to address gaps in treatments for patients with moderate to severe glaucoma
Intends to address gaps in treatments for patients with moderate to severe glaucoma
Established Delivery Technique
Approach provides predictable outcomes
Approach provides predictable outcomes
Latest News
Sep. 6, 2023
Myra Vision Announces Successful First-In-Human Use of its Calibreye™ System, a Next Generation Aqueous Shunt Therapy for Patients with Moderate to Severe Glaucoma
First-of-its-kind titratable glaucoma therapy system aims to optimize reduction of intraocular pressure (IOP)
First-of-its-kind titratable glaucoma therapy system aims to optimize reduction of intraocular pressure (IOP)
Jun. 26, 2023
Myra Vision, a Shifamed Portfolio Company, Closes $25M in Series B Financing
Funding to support product development and initiate clinical experience of first-of-its-kind surgical treatment for patients with moderate to advanced glaucoma
Jun. 1, 2021
Myra Vision, A Shifamed Portfolio Company, Closes $17M In Series A Financings
Company to accelerate development of the first-of-its-kind treatment for patients with moderate to severe glaucoma
Oct. 10, 2019
Myra Medical, A Shifamed Portfolio Company, Closes $3M In Seed Financing
Company is innovating next-generation treatment for moderate to advanced glaucoma